Northwestern Medicine Organ Transplantation Center, Chicago, Illinois.
Northwestern Medicine Organ Transplantation Center, Chicago, Illinois.
J Surg Res. 2024 Nov;303:268-274. doi: 10.1016/j.jss.2024.09.017. Epub 2024 Oct 9.
Kidney transplantation (KT) is the treatment of choice for end-stage renal disease. Diabetes mellitus is the most common indication for KT, with most recipients having type 2 diabetes mellitus (T2DM). Previous studies have shown inferior patient survival in T2DM KT recipients. This single-center study aimed to understand the individual factors associated with negative long-term outcomes.
This is a single-center retrospective analysis of adult KT recipients, with and without T2DM from 2012 to 2017 with a follow-up through December 2022. Primary Outcomes were graft loss and patient survival. Univariate, Multivariate Cox regression, and Kaplan-Meier analyses were used to assess KT outcomes.
We analyzed 1185 patients, 288 (24.3%) with T2DM. T2DM patients tended to be older, 56.6 ± 9.8 versus 47.1 ± 13.7 y. (P < 0.01), male (66.3% versus 58.2% P < 0.001) had a higher body mass index, 31.3 ± 5.4 versus 27.4 ± 5.7 P < 0.01) and less likely to get a living donor transplant (46.5% versus 58.4%, P < 0.01). T2DM patients after KT had a 50% higher risk for graft loss (hazard ratio 1.509, 95% CI 1.15-1.95, P < 0.001) and a 106% higher risk of death (hazard ratio 2.06 (95% CI 1.48-2.87, P < 0.0001). Among the T2DM patients, the most common cause of death was infection (39.9%). The average HbA1c at 1 y after transplant was 7.8%.
The present study shows that T2DM is strongly associated with an increased risk of graft loss and death after KT, particularly in older recipients of deceased donor transplants with longer cold ischemia time that experience delayed graft function. This underscores the importance of avoiding delayed graft function in older, type 2 diabetic kidney transplant recipients and prioritizing living donors.
肾移植(KT)是终末期肾病的首选治疗方法。糖尿病是 KT 的最常见适应证,大多数接受者患有 2 型糖尿病(T2DM)。先前的研究表明,T2DM KT 受者的患者生存率较低。本单中心研究旨在了解与负面长期结果相关的个体因素。
这是一项对 2012 年至 2017 年期间接受 KT 的成年 T2DM 和非 T2DM 患者的单中心回顾性分析,随访至 2022 年 12 月。主要结局是移植物丢失和患者生存。使用单变量、多变量 Cox 回归和 Kaplan-Meier 分析评估 KT 结局。
我们分析了 1185 名患者,其中 288 名(24.3%)患有 T2DM。T2DM 患者年龄较大,56.6±9.8 岁 vs. 47.1±13.7 岁(P<0.01),男性(66.3% vs. 58.2%,P<0.001),体重指数较高,31.3±5.4 岁 vs. 27.4±5.7 岁(P<0.01),活体供者移植的可能性较小(46.5% vs. 58.4%,P<0.01)。KT 后 T2DM 患者移植物丢失风险增加 50%(风险比 1.509,95%CI 1.15-1.95,P<0.001),死亡风险增加 106%(风险比 2.06(95%CI 1.48-2.87,P<0.0001)。在 T2DM 患者中,死亡的最常见原因是感染(39.9%)。移植后 1 年时的平均 HbA1c 为 7.8%。
本研究表明,T2DM 与 KT 后移植物丢失和死亡的风险增加密切相关,尤其是在接受尸肾移植且冷缺血时间较长、发生延迟移植物功能的老年患者中。这突显了避免老年 2 型糖尿病肾移植受者延迟移植物功能并优先选择活体供者的重要性。